We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 31.88M | 27.12M | 18.1652 | 1.32 | 35.84M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/12/2004 12:49 | Update from ... Justice Laddie said Abbott should have paid Cambridge Antibody a royalty rate of "just over 5 percent" of net sales, instead of the 2 percent it received. "It's very good for (Cambridge Antibody) because it will enhance its cash flow and it will be less dependent on the market to raise cash," said Reijer Lenstra, managing director of Biopharma Fund, which manages about $150 million in biotechnology investments. "It really changes the perspective for the company in a big way." Cambridge Antibody's case was "overwhelming," Justice Laddie wrote in his ruling. Laddie said the more he considered arguments submitted by Lord Grabiner QC, Abbott's lawyer, "the more difficult his client's position appears to be." Cambridge Antibody shares were suspended in London today. The company has a market value of 258.1 million pounds ($502 million), based on Friday's closing price. | matthu | |
20/12/2004 12:39 | 365,000 shares traded, currently trading 792-800. Click on Trades and then download the trading history to your PC. | matthu | |
20/12/2004 12:37 | Oop forget that I am now! | danny_boffin | |
20/12/2004 12:36 | I'm seeing the offer prices but I'm not seeing any trades showing... | danny_boffin | |
20/12/2004 12:34 | 800p to buy on Barclays | matthu | |
20/12/2004 12:31 | looks like its still suspended then | jonno1 | |
20/12/2004 12:29 | Strange though, I can't trade yet online - anyone know if any trades are going through yet at all? | danny_boffin | |
20/12/2004 12:28 | bid 800, offer 750 (!) on ADVFN delayed ... | matthu | |
20/12/2004 12:27 | I'm showing 8p at the moment. | danny_boffin | |
20/12/2004 12:20 | sorry comdirect are not, what is the price now please? | jonno1 | |
20/12/2004 12:17 | Think they just have! | danny_boffin | |
20/12/2004 12:15 | when do the shares start re trading? | jonno1 | |
20/12/2004 12:00 | Yes, Abbott will have to pay royalties back to the start date. This judgement will also affect other products covered by the same agreement that will potentially come to the market. Useful background article here: | matthu | |
20/12/2004 11:54 | Company Announcement RNS Number:6142G Cambridge Antibody Tech Group PLC 20 December 2004 FOR IMMEDIATE RELEASE 20 December 2004 For further information contact: Weber Shandwick Square Mile (Europe) Cambridge Antibody Technology Tel: +44 (0) 20 7067 0700 Tel: +44 (0) 1223 471 471 Sarah MacLeod Peter Chambre, Chief Executive Officer John Aston, Chief Financial Officer Rowena Gardner, Director of Corporate Communications BMC Communications/The Trout Group (USA) Tel: +1 212 477 9007 Brad Miles, ext 17 (media) Brandon Lewis, ext 15 (investors) CAMBRIDGE ANTIBODY TECHNOLOGY PREVAILS IN PROCEEDINGS IN HIGH COURT RE: HUMIRA Cambridge, UK... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) reports that in the trial against Abbott in the High Court in London, the trial judge, Mr Justice Laddie announced this morning that he finds in favour of CAT. A full written judgement has been released. Set out below in full is the shorter statement provided by the judge in court. "This morning I am handing down my judgment in this action. Because of its commercial sensitivity, and with the agreement of counsel, I have not adopted the normal procedure of making a draft available in advance. The judgment, which will be available for collection in a moment, is of some length. It is appropriate that I indicate the conclusion I have come to. What I say now is not to be taken as altering, expanding or in any way qualifying what is set out in the full judgment. The parties, Cambridge Antibody Technology (CAT) on one side and Abbott on the other, are parties to an agreement, originally entered into in 1993 and then replaced by another to substantially the same effect in 1995. Under it CAT has licensed Abbott to make use of its ground breaking technology, referred to as library and phage display technology, for the purpose of enabling Abbott to develop, make and sell a genetically engineered human antibody to be used in the treatment of rheumatoid arthritis. The program to develop and make this antibody is lengthy and involves some of the most modern techniques of genetic engineering. CAT's technology is used at an early stage in the program. The program has been successful. Abbott has put upon the market a product containing the antibody. It is called HUMIRA. In a short time, its sales have been substantial. Under the agreements, Abbott is contractually bound to pay royalties to CAT at a rate of just over 5% of the Net Sales of HUMIRA. That royalty obligation is subject to an offset or royalty sharing provision. It allows Abbott to deduct from the royalties due to CAT half of the royalties paid by it for licences from third parties for certain categories of technology. There is a minimum royalty provision of 2%. The parties dispute the extent of this offset or royalty sharing provision. CAT argues that, on its proper construction, the relevant provisions of the 1993 and 1995 Agreements mean that Abbott can only demand that CAT shares royalties in respect of the third party rights covering CAT's library and phage display technology. Abbott argues that it is entitled to require CAT to share 50/50 in the royalty burden it has in respect of all technology it uses throughout the development and production process up to and including the production of the human antibody from host cells. There are no relevant third party rights in respect of the library and phage display part of the development and manufacturing program. For that reason CAT says that it is entitled to the full royalty provided for under the agreement. On the other hand there are a number of such rights in respect of the later parts of the program down to the point at which the antibody is produced. Abbott has paid or undertaken to pay royalties under the latter. Abbott says it can take off half of the royalties it has so incurred. This has taken CAT's entitlement down to the minimum guaranteed under the agreement, namely 2%. In late 2003 Abbott began paying royalties to CAT under the 1995 Agreement. It did so at the 2% level. CAT argues that it should have paid and should continue to pay the full royalty due under the agreement without deduction. Hence this action. Besides arguing that its construction of both agreements is correct, CAT also argues that, if it is wrong on that, the agreements do not reflect the true intention of the parties. It says that such common intention was to limit CAT's obligation to share royalties so that it only applied to royalties in respect of third party rights covering the library and phage display technology which it licensed to Abbott. It therefore asks for the court to order rectification so that the words of the agreement accord with that common intention. Alternatively it asks for the agreements to be rectified on the ground of unilateral mistake, on the basis that Abbott has behaved unconscionably in advancing the argument it does in this action. For the reasons set out in my judgment, I have come to the conclusion that the construction advanced by CAT is correct and that the construction advanced by Abbott does violence to the language of the agreements, renders them obscure and makes little or no commercial sense. For this reason CAT wins this action. I have also considered the common mistake and rectification arguments. In relation to them I was taken through a large number of the parties' documents spread over some years and the evidence of a number of witnesses. For the reasons set out in my judgment I have come to the conclusion that it is overwhelmingly likely that CAT's case as to what was the mutual and real intention and agreement of the parties is correct. It follows that, had I not found in its favour in relation to the issue of construction, I would have ordered rectification of the agreements to ensure that they accorded with the true intention of the parties, namely that CAT's royalty sharing obligations should extend only to third party rights which covered its library and phage display technology and no further. It follows that Abbott was in error when it made its first royalty payment to CAT calculated on the basis that only 2% of the Net Sales was due. It should have calculated on the basis of the full royalty of just over 5% and should have paid and continued to pay CAT accordingly." Abbott made an application this morning for permission to appeal, which will not be heard before late January. -ENDS- Notes to Editors Cambridge Antibody Technology (CAT): * CAT is a biopharmaceutical company using its proprietary technologies and capabilities in human monoclonal antibodies for drug discovery and drug development. Based near Cambridge, England, CAT currently employs around 280 people * CAT is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company's strategy to develop a portfolio of antibody-based drugs. * Four CAT human therapeutic antibody products are now at various stages of clinical development, with one further product candidate in pre-clinical development. * HUMIRA, the leading CAT-derived antibody, isolated and optimised in collaboration with Abbott, has been approved for marketing as a treatment for rheumatoid arthritis in 51 countries. Six further licensed CAT-derived human therapeutic antibodies are in clinical development by licensees, with four further licensed product candidates in pre-clinical development. * CAT has alliances with a number of pharmaceutical and biotechnology companies to discover, develop and commercialise human monoclonal antibody-based products. * On 22 November 2004, CAT announced a strategic alliance with AstraZeneca to discover and develop human antibody therapeutics in inflammatory disorders. * CAT has a broad collaboration with Genzyme for the development and commercialisation of antibodies directed against TGF, a family of proteins associated with fibrosis and scarring. This collaboration has so far given rise to one antibody product candidate at clinical development stage, and one at pre-clinical development stage. * CAT has also licensed its proprietary technologies to several companies. CAT's licensees include: Abbott, Amgen, Chugai, Genzyme, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research. * CAT is listed on the London Stock Exchange and on NASDAQ. CAT raised #41m in its IPO in March 1997 and #93m in a secondary offering in March 2000. Application of the Safe Harbor of the Private Securities Litigation Reform Act of 1995: This press release contains statements about Cambridge Antibody Technology Group plc ("CAT") that are forward looking statements. All statements other than statements of historical facts included in this press release may be forward looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward looking statements are based on numerous assumptions regarding the company's present and future business strategies and the environment in which the company will operate in the future. Certain factors that could cause the company's actual results, performance or achievements to differ materially from those in the forward looking statements include: market conditions, CAT's ability to enter into and maintain collaborative arrangements, success of product candidates in clinical trials, regulatory developments and competition. We caution investors not to place undue reliance on the forward looking statements contained in this press release. These statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements. | matthu | |
20/12/2004 11:53 | Does Abbott have to back date the royalty payments? | bungles | |
20/12/2004 11:41 | from Biotech Pioneer Wins Royalties Battle By Mike Taylor, PA Pioneering biotech company Cambridge Antibody Technology (CAT) today won its multi-million pound High Court battle to more than double the royalties it is paid on the massive sales of the arthritis drug Humira. A judge in London ruled that US-based pharmaceuticals giant Abbott Laboratories, which was licensed to use CAT's ground-breaking technology in developing the drug, should be paying royalties at the rate of just over 5% of net sales instead of the 2% it has been paying for the past year. Mr Justice Laddie said Abbott's interpretation of its licensing agreements with CAT "does violence to the language of the agreements, renders them obscure and makes little or no commercial sense." | matthu | |
20/12/2004 11:40 | Onle after a company announcement from CAT, which is presumably being prepared as we chat. I expect Abbott will want to appeal, though it would be nice to hear a little contrition from their side. Remember how the initial decision to cut CAT's royalty blew their chances of taking over Oxford Glycosciences ... Abbott must have their hands full at the moment simply trying to restore their reputation as a good partner to be doing deals with, so it will be interesting to see whether they appeal and how they couch their response to the verdict today. | matthu | |
20/12/2004 11:34 | Does anyone know when the suspension of CAT share trading is likely to cease? | bungles | |
20/12/2004 11:19 | Cambridge Antibody Wins Lawsuit Against Abbott Labs (Update1) Dec. 20 (Bloomberg) -- Cambridge Antibody Technology Group Plc won a court ruling awarding it higher royalties from U.S. partner Abbott Laboratories for helping develop one of the biggest drugs from the U.K.'s biotechnology industry. Cambridge Antibody claimed Abbott unfairly cut its royalties to pay other companies holding patents for techniques used to make Humira, a rheumatoid arthritis treatment. Abbott said it was entitled to slash the payments in order to pay royalties to Genentech Inc., which also helped develop Humira, and rejected allegations it has behaved dishonestly. "The construction advanced by CAT is correct," Justice Hugh Laddie told the High Court in London today. "The construction advanced by Abbott does violence to the language of the agreement, renders them obscure and makes little or no commercial sense." The case pitted century-old Abbott, which has a market value of $73.2 billion, against an unprofitable company founded in 1989 with the help of scientists from Cambridge University and the British Medical Research Council. Cambridge Antibody shares were suspended in London today. The company has a market value of 258.1 million pounds ($502 million), based on Friday's closing price. Fastest-Growing Sales of Humira, the drugmaker's fastest-growing medicine, are expected to hit $1.2 billion next year, Abbott says. The Abbott Park, Illinois-based company said Dec. 17 that it had asked the U.S. Food and Drug Administration to approve Humira's use to treat psoriatic arthritis. Abbott gained Humira in 2001 when it bought BASF AG's Knoll drug business, which had an agreement with Cambridge Antibody for the therapy at the time. Cambridge Antibody's suit against Abbott opened 13 days after the Cambridge, England-based company said that Trabio, its most advanced drug in development, failed in trials. AstraZeneca Plc, Europe's third-largest drugmaker, on Nov. 22 bought a 19.9 percent stake in Cambridge Antibody to form a research alliance. Abbott was founded in 1888 by Wallace C. Abbott, in his apartment based above his pharmacy. The case is HC03CO3963, Cambridge Antibody Technology Ltd. v Abbott Biotechnology Ltd. Lord Grabiner QC, Simon Thorley QC and Freshfields Bruckhaus Deringer, which replaced Slaughter & May, are acting for Abbott, while Geoffrey Vos QC, David Kitchin QC and Herbert Smith are representing Cambridge Antibody. | matthu | |
20/12/2004 11:08 | Justice is served......Happy Christmas everyone. | dancer03 | |
20/12/2004 11:05 | Way to go CAT! | matthu | |
20/12/2004 11:00 | Good stuff! So how high is it gonna go today when they resume? | danny_boffin | |
20/12/2004 10:52 | Yippeeee!!! Congratulations to the CAT management team and lawyers for having the bottle to stand up and fight big pharma. The biotech industry has been shafted by big pharma too many times over recent years. Well done guys. | bungles | |
20/12/2004 10:51 | At the moment I'm only buying the UK market - probably a mistake I know. I recently topped up with more CAT and also with Skyepharma. Been looking at Bioprogress which is today again being subject to shorting, and also at MICAP which has an interesting mix of pharma and non-pharma applications, and a sizeable investment from SKP. | matthu |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions